Achaogen Stock

Achaogen Equity

Delisted

The The Equity of Achaogen (AKAOQ) as of Aug 13, 2026 is -6.29 M USD. In the previous year, The Equity was 121.96 M USD — a change of -105.15% (lower).

Equity

-6.29 MUSD

YoY

-105.15%

Last updated:

In 2026, Achaogen's equity was -6.29 M USD, a -105.15% increase from the 121.96 M USD equity in the previous year.

Access this data via the Eulerpool API

Achaogen Stock analysis

What does Achaogen do? Achaogen Inc is an innovative biotechnology company specializing in the development of antibiotics for the treatment of life-threatening infectious diseases. The company's business model is based on research and development of new antibiotics, aiming to improve medical care for patients with infections. Achaogen was founded in 2002 by a team of researchers and professionals in the biotechnology industry and has developed several products for the treatment of diseases such as pneumonia, urinary tract infections, and bloodstream infections. The company's main divisions include Plazomicin, Zemdri, and C-Scape, which are antibiotics targeting different types of infections. Achaogen is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Achaogen's Equity

Achaogen's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Achaogen's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Achaogen's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Achaogen's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Achaogen’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Achaogen stock

The Equity of Achaogen is -6.29 M USD in 2026.

The Equity of Achaogen changed from 121.96 M USD to -6.29 M USD, representing a -105.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Achaogen since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Achaogen historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Achaogen

All Key Metrics — Achaogen